Automation in Biopharma Industry Market to grow with a CAGR of 5.80%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Automation in Biopharma Industry Market.
According
to TechSci Research report, “Global Automation in Biopharma Industry Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Automation in Biopharma
Industry Market has valued at USD 1775.20 million in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 5.80%
through 2028. This can be due to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market. Data-driven
decision-making is a significant driver of the demand for automation in the
Global Automation in Biopharma Industry Market. The biopharma industry
generates massive amounts of data during research, development, and
manufacturing processes. Automation systems are essential for handling and
managing this vast volume of data efficiently. Data in biopharma often involves
intricate biological, chemical, and process information. Automation facilitates
complex data analysis, making it easier for researchers and decision-makers to
extract meaningful insights from the data. Automation technology allows for
real-time monitoring of various bioprocesses. This real-time data provides
immediate feedback, enabling timely decision-making and adjustments to ensure
product quality and process optimization. Data-driven decision-making relies on
predictive modeling to anticipate outcomes and optimize processes. Automation
systems can be integrated with machine learning and artificial intelligence
algorithms to develop predictive models based on historical data.
Data-driven
analysis allows biopharma companies to identify potential risks early and take
preventive measures. Automation systems provide the data needed to assess and
mitigate risks effectively. Automation systems collect data over time, enabling
continuous process improvement. Data-driven decision-making informs strategies
for enhancing efficiency, product quality, and cost-effectiveness.
In
the biopharma industry, automation entails the application of cutting-edge
technologies and software to mechanize a range of activities in both
biopharmaceutical manufacturing and research. This encompasses the automation
of laboratory procedures, manufacturing processes, quality assessment, and data
interpretation. The primary objective of automation in the biopharma industry
is to enhance operational efficiency, accelerate processes, and enhance
precision while concurrently decreasing errors and reducing the need for
extensive human involvement. This automation may encompass the utilization of
robotics, sensors, artificial intelligence, and other advanced technologies to
optimize production procedures and elevate productivity.
In February 2023, Siemens Healthineers, a prominent
medical technology company, and Unilabs, a leading provider of diagnostic
services, have jointly announced a multi-year agreement with a value exceeding
€200 million. Unilabs is making a substantial investment in Siemens
Healthineers' cutting-edge technology, acquiring more than 400 laboratory
analyzers to further enhance and upgrade its laboratory infrastructure. This
strategic move is aimed at delivering an exceptional level of service to its
customers. Within the framework of this agreement, Unilabs will continue its
ongoing efforts to modernize its healthcare infrastructure across its network,
with a primary focus on enhancing customer service and quality, ultimately
leading to improved patient healthcare outcomes. The solutions provided by
Siemens Healthineers will play a pivotal role in elevating Unilabs' laboratory
operations, improving throughput, and ensuring clinical excellence throughout
its testing network.
Ethical
concerns in the Global Automation in Biopharma Industry Market can be a
significant challenge, particularly in the context of research, development,
and manufacturing of biopharmaceutical products. Automation systems in the
biopharma industry often handle sensitive patient data and intellectual
property. Ensuring the privacy and security of this data is a critical ethical
concern. Breaches or unauthorized access to patient information or proprietary
research can have serious consequences. In the context of personalized medicine
and clinical trials, ethical considerations include obtaining informed and
voluntary consent from patients whose data and samples are being used in
research. Ensuring that patients understand the implications of their participation
is essential. Biopharmaceutical companies must be transparent about the use of
automation technology and how it impacts research and manufacturing processes.
Ethical concerns arise when patients or researchers are not fully informed
about the use of automation or its potential implications. The use of
automation can lead to increased costs in drug development and manufacturing.
Ethical concerns revolve around ensuring that lifesaving or life-improving
therapies remain accessible and affordable to all patients, rather than being
prohibitively expensive.
Browse
over XX market data Figures and spread through XX Pages and an in-depth TOC on
" Global Automation in Biopharma Industry Market.”
Global Automation in Biopharma Industry Market is
segmented based on Technology, Application, Component, and by region. Based on the Technology, Global Automation in
Biopharma Industry Market is segmented into Automation Technology, Digitization Technology. Automation
technology in the biopharmaceutical (biopharma) industry encompasses a wide
range of innovative tools and systems designed to streamline and enhance
various processes across research, development, and manufacturing. These
technologies play a crucial role in improving efficiency, data quality, and the
overall production of biopharmaceutical products. Laboratory automation
technology includes robotic systems, liquid-handling platforms, and
sophisticated software that enable precise and high-throughput processing of
samples. Automated liquid handlers, for example, can accurately dispense
reagents and samples in various assays, speeding up experiments and minimizing
human errors. Automation technology is used in biopharmaceutical manufacturing
to control and monitor critical process parameters. This includes automated
systems for managing cell culture, fermentation, purification, and other
manufacturing steps. These systems ensure consistent product quality and reduce
the risk of variations.
Based on Region, North America held the largest share in the Global Automation in Biopharma Industry Market.
North America has a well-educated and skilled workforce in the fields of
biopharmaceuticals, engineering, and automation, which supports the
implementation and maintenance of automation systems. The region has a large
and growing market for biopharmaceutical products, including drugs and
therapies, which drives the need for automation to meet increasing production
demands efficiently. North American companies and research institutions are at
the forefront of biopharmaceutical research and development. Automation is
crucial in accelerating drug discovery and development processes. The region
fosters collaboration between academia, government agencies, and the private
sector. This collaborative ecosystem facilitates knowledge sharing and
technology adoption. Strong intellectual property protection in North America
encourages companies to invest in automation as a means of protecting their
proprietary processes and innovations.
Some
of the major companies operating in the Global
Automation in Biopharma Industry Market include:
- PerkinElmer,
Inc.
- AMETEK,
Inc.
- Autodesk,
Inc.
- Baumueller-Nuermont
Corp
- Emerson
Electric Co.
- Kawasaki
Robotics
- RheoSense
Inc.
- Rockwell
Automation, Inc.
- Sartorius
Stedim Biotech SA
- Siemens
Healthineers
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Automation in Biopharma
Industry. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Automation in Biopharma Industry Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Automation in Biopharma Industry Market by Technology (Automation Technology, Digitization
Technology), By Application (Clinical Phase, Drug Discovery Phase, Production
Phase), by Component (Automation Hardware, Automation Software, Services
Project Phase, Services Operation Phase), By
Region, By Competition Forecast
& Opportunities, 2018-2028F has
evaluated the future growth potential of Global Automation in Biopharma
Industry Market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Automation in
Biopharma Industry Market.
Contact
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com